Poolbeg Pharma "in a very healthy cash position" after first full year of operations | News Direct

Poolbeg Pharma "in a very healthy cash position" after first full year of operations

Poolbeg Pharma PLC
News release by Poolbeg Pharma PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | March 30, 2023 04:08 AM Eastern Daylight Time

 

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after publishing final results for 2022 that show that the clinical-stage biotech company finished its first full year of operations with £16.2mln. Skillington describes it as a "very healthy cash position" and summarises his main highlights from the year, before looking ahead to what the market can expect from Poolbeg during the rest of 2023.

 Here is the earlier story: 

 Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) has said it is working towards its first partnering ‘transaction’ for POLB 001 after a successful period in which it conducted a first human challenge study on its lead asset to assess its potential in severe flu.

On its own, this would be a significant achievement. However, the drug developer has been active in broadening its pipeline in 2022 – adding POLB 002 for severe respiratory virus infections and POLB 003 for melioidosis.

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

HealthPharmaBiotechLupusHuman Challenge StudyInfluenza